Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Glioma Stories

2014-02-26 08:28:38

Interim clinical data to be presented at American Association of Cancer Research (AACR) Annual Meeting on April 9, 2014 VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 26, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") provided an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 5 and advanced to Cohort 6. DelMar...

2014-02-04 11:57:02

Largest-ever study of 20-year survival among pediatric low-grade glioma patients highlights radiation's association with higher mortality The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults. However, children who received radiation as part of their treatment had significantly lower long-term...

2014-02-04 11:02:59

Presence of IDH1 mutation determines best treatment for malignant astrocytomas Astrocytomas are the most common malignant brain tumors. While most patients' tumors prove to be quite aggressive, outcomes overall can vary widely, with some patients surviving for many years. Now a new study has found that malignant astrocytoma patients whose tumors carry a specific genetic mutation benefit greatly from surgical removal of the largest possible amount of tumor. Preliminary results of the study...

2014-01-13 08:30:13

Topline Data Will Be Presented at Biotech Showcase HEIDELBERG, Germany, Jan. 13, 2014 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today the successful completion of its phase II proof-of-concept trial with APG101 in patients with recurrent glioblastoma. All endpoints of the randomized controlled trial that compared the efficacy and safety of a combination therapy of APG101 and radiotherapy versus radiotherapy alone were achieved or...

2013-12-27 23:04:45

In response to an article published by Medical News Today (MNT), Voices Against Brain Cancer discusses a new brain tumor vaccine that is personalized to each patient. New York, NY (PRWEB) December 27, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by Medical News Today that discusses a new brain cancer vaccine called HSPPC-96, which is personally molded to each patient’s genetic makeup. According to the...

2013-12-16 18:14:37

Rates of programmed cell death higher in mice treated with experimental drug than in untreated animals with same cancer An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology (ASCB) annual meeting in New Orleans. The...

2013-12-11 23:25:34

In response to an article published by Medical News Today, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, discusses a new test that may revolutionize the way medical experts diagnose brain cancer. New York, NY (PRWEB) December 11, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by Medical News Today on November 29th that discusses how a new technique developed...

2013-12-11 04:21:11

LONDON, Dec. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma. Glioma...

2013-12-10 23:33:21

In response to an article published by Science Daily, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, discusses the results of an immune system study that could lead to the cure of a hostile malignant brain tumor. New York, NY (PRWEB) December 10, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research, responds to an article published by Science Daily on November 25th, which discusses the results generated from...

2013-12-09 14:05:31

Researchers identify mechanism implicated in brain cancer and a drug that decreases brain tumor growth Researchers at the University of Calgary's Hotchkiss Brain Institute (HBI) have made a discovery that could lead to better treatment for patients suffering from brain cancer. Despite current treatment strategies, the median survival for patients with the most aggressive brain cancer – called glioblastoma, is 15 months. Less than five per cent of patients survive beyond five years....